Getting to grips with the multitude of early scientific findings: lessons from the pandemic
Heidelberg, 22 December 2020 – EMBO publicly launches the Early Evidence Base site (https://eeb.embo.org), an experimental platform that blends human scientific expertise with artificial intelligence (AI) to highlight scientific findings posted in preprints. Preprints are manuscripts that are publicly shared online by researchers before formal publication in a peer-reviewed journal.
Biomarkers could help predict severe SARS-CoV-2 infection
Heidelberg, 14 December 2020 – Molecular markers in the blood shown to be predictive of severe COVID-19 outcomes resulting from SARS-CoV-2 coronavirus infection have been identified in a study by a Chinese research team.
Nine life scientists become EMBO Global Investigators
Heidelberg, 3 December 2020 – EMBO congratulates nine life scientists on their selection as EMBO Global Investigators. They form the second cohort of the Global Investigator Network that was launched in 2019 and will start their four-year tenure in January 2021. The new Global Investigators will receive financial support for several networking, collaboration and training activities.
EMBO welcomes thirty Young Investigators
Heidelberg, 1 December 2020 – EMBO is pleased to announce that thirty life scientists have been selected as EMBO Young Investigators. They will join the existing network of 73 current and 384 former members of the programme. The new EMBO Young Investigators will receive financial and practical support for a period of four years, starting in January 2021.
Sarah-Maria Fendt and Markus Ralser awarded EMBO Gold Medal 2020
Heidelberg, 14 October 2020 — This year’s EMBO Gold Medal is going to two researchers who study cell metabolism, Sarah-Maria Fendt and Markus Ralser. Every year, EMBO awards the Gold Medal to scientists under the age of 40 in recognition of outstanding achievements in the life sciences. The award consists of a gold medal and a cash prize of € 10,000.
“Mini brain” organoids show potential for SARS-CoV2 to cause neurodegenerative- disease-like effects
Heidelberg, 3 September 2020 - New research published today in The EMBO Journal reports that the SARS-CoV-2 coronavirus can target human neurons with the potential to cause disease of the central nervous system (CNS). The research showed that the virus can enter tiny laboratory-developed 3D structures called brain organoids that replicate key aspects of the human brain and induce pathological effects similar to early stages of diseases of the CNS such as Alzheimer’s.
Naturally occurring antibodies against prion proteins found in humans
Heidelberg, 10 August 2020 - Antibodies targeting the normal PrP version of the prion protein have been found in humans selected at random with no history of any associated transmissible spongiform encephalopathies.
EMBO announces newest elected members
Heidelberg, 7 July 2020 - EMBO has bestowed upon 63 leading scientists the lifetime honour of EMBO Membership in recognition of their remarkable achievements in the life sciences, it was announced today.
New EMBO Fellowships for Core Facility staff
Heidelberg 25 February 2020 – EMBO announces an extension of its current Short-Term Fellowship scheme: Core Facility Fellowships. These fellowships will support exchanges of technology and expertise between core research facilities that provide services to research institutions or universities.
Elly Tanaka receives the FEBS | EMBO Women in Science Award 2020
Heidelberg, 18 February 2020 – EMBO and FEBS announce Elly Tanaka of the Research Institute of Molecular Pathology, Vienna BioCenter, Austria, as the recipient of the FEBS | EMBO Women in Science Award 2020.
Eleven researchers receive EMBO Installation Grants to establish independent laboratories
Updated version, issued 20 February 2020, replacing the press release issued 15 January 2020
Heidelberg 15 January 2020 – EMBO is pleased to announce that eleven life scientists have been selected to receive Installation Grants, which will support them in establishing independent laboratories in the Czech Republic, Poland, Portugal and Turkey.